Celeris Therapeutics, Inc. — Form D
Celeris Therapeutics, Inc. of GRAZ, C4, a company, filed a Form D exempt-offering notice with the SEC on 2022-02-24. The offering totals $4.7M, of which $3.0M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2022-02-24
- Form: D
- Accession: 0001913452-22-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $4.7M
- Amount sold: $3.0M
- Remaining: $1.8M
- Investors: 5
- Date of first sale: 2022-02-09
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-434920
Issuer
- Name: Celeris Therapeutics, Inc.
- CIK: 0001913452
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: LEDERMOARWEG 25/6, GRAZ, C4, 8010
- Phone: 43 660 55 86 512
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Jakob-Ferdinand Hohenberger | Director | Graz, C4 |
| Karel Kubias | Director | Graz, C4 |
| Petr Sramek | Director | Miami, FL |
| Marius Swart | Director | Graz, C4 |
| Christopher Trummer | Director | Graz, C4 |
| Jakob-Ferdinand Hohenberger | Executive Officer | Graz, C4 |
| Christopher Trummer | Executive Officer | Graz, C4 |
More